SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
-
Views:
21790
-
Likes:
7
Overview
Full programme
-
Views:
21790
-
Likes:
7
Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm
Overview
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
Target Audience
- Cardiologists
- Nephrologists
- Endocrinologists
More from this programme
Part 1
State of the Art 1
Part 2
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Part 3
Meet The Expert: Implications for Clinical Practice - Breakout 1
Part 4
Meet The Expert: Implications for Clinical Practice - Breakout 2
Part 5
Meet The Expert: Implications for Clinical Practice - Breakout 3
Part 6
State of the Art 2
Part 7
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Part 8
Meet The Expert: Implications for Clinical Practice - Breakout 4
Part 9
Meet The Expert: Implications for Clinical Practice - Breakout 5
Part 10
Meet The Expert: Implications for Clinical Practice - Breakout 6
Faculty Biographies

Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Andrew Coats is President of the Heart Failure Association and Professor of Cardiology, University of Warwick, UK. He is an Australian-British academic cardiologist and inventor. Prof Coats' main interest is heart failure.
From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine of the University of Sydney.
He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor.
Prof Coats is Editor-in-Chief of the Cardiac Failure Review editorial board.